Bristol Myers to Divest Nutritional Division, reported by chartpoppers.com
To find more information on Bristol Myers Squibb Co. (NYSE:BMY) and other big board companies, Sign up to receive updates and Investment coverage from Chartpoppers.com
(EMAILWIRE.COM, November 17, 2009 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Bristol Myers Squibb Co. (NYSE: BMY)
The Consolidated Investment Analysis on Bristol Myers Squibb Co.. will be in particular interest to other companys in the Healthcare sector, such as Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK) and Eli Lilly & Co. (NYSE: lly)
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers
Recent News on Bristol Myers Squibb Co. (NYSE:BMY)
Bristol-Myers Squibb announced plans on Monday to divest its nutritional division, Mead Johnson Nutrition, in a $6.5 billion deal. The move would allow Bristol-Myers to focus more on its pharmaceutical business, something CEO James Cornelius has said is a goal for the company.
Bristol-Myers took steps earlier this year to spin off the division, holding an IPO of the stock worth a 17% stake.
As part of the agreement, Bristol-Myers shareholders must purchase 144.5 million out of the 170 million shares currently owned by Bristol-Myers before the deal can go through.
Shareholders can exchange $1 of Bristol-Myers common shares for $1.11 of Mead Johnson stock.
Shares of Bristol-Myers rose 4.8% Monday to $24.30.
To view the Consolidated Investment Analysis on Bristol Myers Squibb Co. (NYSE:BMY)Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The Consolidated Investment Analysis on Bristol Myers Squibb Co.. will be in particular interest to other companys in the Healthcare sector, such as Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK) and Eli Lilly & Co. (NYSE: lly)
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers
Recent News on Bristol Myers Squibb Co. (NYSE:BMY)
Bristol-Myers Squibb announced plans on Monday to divest its nutritional division, Mead Johnson Nutrition, in a $6.5 billion deal. The move would allow Bristol-Myers to focus more on its pharmaceutical business, something CEO James Cornelius has said is a goal for the company.
Bristol-Myers took steps earlier this year to spin off the division, holding an IPO of the stock worth a 17% stake.
As part of the agreement, Bristol-Myers shareholders must purchase 144.5 million out of the 170 million shares currently owned by Bristol-Myers before the deal can go through.
Shareholders can exchange $1 of Bristol-Myers common shares for $1.11 of Mead Johnson stock.
Shares of Bristol-Myers rose 4.8% Monday to $24.30.
To view the Consolidated Investment Analysis on Bristol Myers Squibb Co. (NYSE:BMY)Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
